Advances in Therapy | Page 2

Blaine T Phillips, Emma S Sheldon, Vwaire Orhurhu, Robert A Ravinsky, Monika E Freiser, Morteza Asgarzadeh, Omar Viswanath, Alan D Kaye, Marie Roguski
INTRODUCTION: Surgical site infection (SSI) following spinal surgery is a major source of postoperative morbidity. Although studies have demonstrated perioperative antimicrobial prophylaxis (AMP) to be beneficial in the prevention of SSI among spinal surgery patients, consensus is lacking over whether preoperative or extended postoperative AMP is most efficacious. To date, no meta-analysis has investigated the comparative efficacy of these two temporally variable AMP protocols in spinal surgery...
May 15, 2020: Advances in Therapy
Yi-Xin Zhao, Yu-Lu Sun, Jia-Hui Ye, Yin Zhang, Xian-Biao Shi, Jing-Mei Wang, Hong-Yan Wu, Wei-Jie Zhang, Yong-Zhong Yao
INTRODUCTION: This study aims to investigate the relationship between breast white adipose tissue (WAT) inflammation and being overweight or obese, menopausal status, and metabolic syndrome-related indicators in breast cancer patients as well as the association between adipocyte size and the severity of WAT inflammation and body mass index (BMI). METHODS: The crown-like structures (CLS-B) formed by macrophages surrounding dying or dead adipocytes can be used to identify breast WAT inflammation...
May 15, 2020: Advances in Therapy
Shadan Lalezari, Michaël Acquadro, Elodie de Bock, Jérémy Lambert, Mindy L Simpson
INTRODUCTION: BAY 94-9027 is a newly developed extended half-life product to treat haemophilia, allowing for fewer injections than with standard products. This post hoc analysis aimed to compare physicians' and patients' opinions on BAY 94-9027 prophylaxis, and explore how qualitative interview data is aligned with the data from the Haemophilia-specific Quality of Life questionnaire for Adults (Haemo-QoL-A). METHODS: Exploratory qualitative interviews were conducted with physicians and patients by phone upon the exit of patients from the PROTECT VIII extension phase following a semi-directed guide...
May 14, 2020: Advances in Therapy
Mario Cozzolino, Eugeniy Shilov, Zuo Li, Masafumi Fukagawa, Saeed M G Al-Ghamdi, Ronald Pisoni, Brian Bieber, Bhadrish Vallabh, Deepa H Chand
INTRODUCTION: This analysis explored laboratory mineral and bone disorder parameters and management of secondary hyperparathyroidism in patients undergoing hemodialysis in Belgium, Canada, China, France, Germany, Italy, Japan, Russia, Saudi Arabia, Spain, Sweden, the UK, and the USA. METHODS: Analyses used demographic, medication, and laboratory data collected in the prospective Dialysis Outcomes and Practice Patterns Study (2012-2015). The analysis included 20,612 patients in 543 facilities...
May 14, 2020: Advances in Therapy
Stephanie J Estes, Ahmed M Soliman, Marko Zivkovic, Divyan Chopra, Xuelian Zhu
INTRODUCTION: To compare all-cause and endometriosis-related healthcare resource utilization (HCRU) and healthcare costs by service categories (outpatient, inpatient, emergency room [ER], pharmacy) among patients with newly diagnosed endometriosis using opioids compared to patients with endometriosis not using opioids. METHODS: A retrospective analysis of IBM® MarketScan® Commercial Claims data from 2009 to 2018 was performed for women aged 18-49 with newly diagnosed endometriosis (International Classification of Diseases (ICD)-9 code 617...
May 12, 2020: Advances in Therapy
Shaum M Kabadi, Aimee Near, Keiko Wada, Chakkarin Burudpakdee
INTRODUCTION: Amidst a changing treatment landscape, real-world evidence on the burden of chronic lymphocytic leukemia (CLL) is limited. The purpose of this study was to describe treatment patterns, adverse events (AEs), and economic burden among treated patients with CCL. METHODS: A retrospective cohort study was conducted with IQVIA PharMetrics® Plus. Patients at least 18 years old with CLL treatment between November 1, 2013 and May 31, 2018 were identified; index date was first observed CLL treatment...
May 12, 2020: Advances in Therapy
Parvez Sheikh, Varut Lohsiriwat, Yury Shelygin
INTRODUCTION: Hemorrhoidal disease (HD) is a common and recurrent problem for many adults worldwide. Venoactive drugs, such as micronized purified flavonoid fraction (MPFF; Daflon® ), have been used to treat HD and their clinical benefits have been demonstrated in previous meta-analyses of clinical trials. The aim of this study was to evaluate the efficacy of MPFF across the broader spectrum of signs and symptoms following treatment of patients with HD. METHODS: We performed a systematic review of the literature to identify randomized clinical trials in which MPFF treatment was compared to placebo or no treatment for acute HD or for relief of symptoms after patients had undergone medical management or a surgical procedure to remove hemorrhoids...
May 12, 2020: Advances in Therapy
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle
Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is a novel third-generation ALK TKI that is able to penetrate the blood-brain barrier and has broad-spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second-generation ALK TKIs...
May 12, 2020: Advances in Therapy
Nigel S Cook, Kyle Landskroner, Bhavik Shah, Susann Walda, Olivia Weiss, Vikrant Pallapotu
INTRODUCTION: Pigmented villonodular synovitis (PVNS), also known as giant-cell tumour of the tendon sheath (GCTT), is a rare, benign proliferative tumour affecting the inner lining of synovial joints and tendon sheets. Information on treatment needs of PVNS patients to inform drug development is currently scarce. We conducted an exploratory qualitative study with PVNS patients to generate insights into the objective and emotional aspects related to their medical journey and experiences of living with this disease...
May 11, 2020: Advances in Therapy
Liudmila M Mikhaleva, Aleksandr I Davydov, Olga I Patsap, Elizaveta V Mikhaylenko, Vladimir N Nikolenko, Margarita E Neganova, Sergey G Klochkov, Siva G Somasundaram, Cecil E Kirkland, Gjumrakch Aliev
This review focuses on pathogenesis of endometriosis, its possible biomarkers and role in endometriosis-associated ovarian cancer. We analyzed various databases to obtain new insights, theories, and biomarkers associated with endometriosis. There are several theories of endometriosis development and biomarker changes including atypical forms. A number of studies have attempted to establish specific, reliable biomarkers to help diagnose endometriosis and endometriosis-associated diseases on the basis of different pathogenetic pathways...
May 8, 2020: Advances in Therapy
Jonathan K Kish, Debanjana Chatterjee, Yin Wan, Hsing-Ting Yu, Djibril Liassou, Bruce A Feinberg
INTRODUCTION: Lenvatinib has become the most commonly prescribed first-line (1L) agent for the treatment of radioactive iodine-refractory differentiated thyroid cancer (RAI-r DTC) since its approval in 2015. With no real-world studies describing clinical outcomes of 1L lenvatinib and subsequent therapy, the current study aimed to assess treatment sequencing and related clinical outcomes in patients treated with 1L lenvatinib in the USA METHODS: We conducted a multisite, retrospective chart review of US patients with a diagnosis of RAI-r DTC who had initiated 1L therapy with lenvatinib from January 1, 2016 through May 31, 2017 with follow-up through October 17, 2018...
May 7, 2020: Advances in Therapy
Tao Jiang, Hao Chen, Jianwei Zheng, Bin Du, Baoyu Yang, Qing Liu, Dongta Zhong, Xinli Wang, Han Wang, Mengxin Lin, Jinhuo Lai, Peifeng Hou, Xiaoyan Lin
INTRODUCTION: Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC). To counter chemotherapy-induced side effects, use of maintenance therapy is suggested. Therefore, we evaluated the efficacy and safety of cetuximab maintenance therapy in patients after effective completion of first-line induction therapy. METHODS: This prospective study enrolled untreated patients with mCRC RBWT who received first-line cetuximab plus FOLFIRI therapy...
May 7, 2020: Advances in Therapy
Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Chihiro Kondoh, Isao Oze, Kyoko Kato, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
INTRODUCTION: In patients with advanced gastric cancer refractory to chemotherapy, the treatment options are limited. Via this phase II study, we aimed to assess the efficacy and safety of oxaliplatin in combination with 5-fluorouracil and l-leucovorin (modified FOLFOX6). METHODS: Patients who had histologically confirmed metastatic gastric cancer refractory to ≥ two previous chemotherapy regimens were included. The primary endpoint was the overall response rate (ORR) by an independent central review...
May 7, 2020: Advances in Therapy
Uta Kiltz, Petros P Sfikakis, Karl Gaffney, Paul-Gunther Sator, Ralph von Kiedrowski, Andreas Bounas, Nicola Gullick, Curdin Conrad, Dimitris Rigopoulos, Eric Lespessailles, Marco Romanelli, Pierre-Dominique Ghislain, Jan Brandt-Jürgens, Rasho Rashkov, Maher Aassi, Roberto Orsenigo, Chiara Perella, Effie Pournara, Sven Gathmann, Piotr Jagiello, Justyna Veit, Matthias Augustin
INTRODUCTION: Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term clinical responses and a consistently favourable safety profile across phase 3 trials. Here, we report the clinical data at enrolment from SERENA, designed to investigate the real-world use of secukinumab across all three indications...
May 6, 2020: Advances in Therapy
Steven L Wright
INTRODUCTION: Controversy and uncertainty exist about the use of benzodiazepine receptor agonists (BZRAs) in pain management. This article curates available research to determine the appropriate role of BZRAs in the course of pain management, and how prescribers might address these challenges. METHODS: A narrative review was performed to determine the appropriate role of BZRAs in pain management and to develop practice recommendations. Publications were identified by a search of PubMed, references of retrieved reports, guidelines, and the author's personal files...
May 6, 2020: Advances in Therapy
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev
INTRODUCTION: The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS: Pooled data from 20 trials were analyzed for patients with T2DM treated with empagliflozin 10 mg (n = 4858), empagliflozin 25 mg (n = 5057), or placebo (n = 4904). The dataset comprised 15 randomized phase I-III trials, an extension trial and dose escalation studies...
May 5, 2020: Advances in Therapy
Jane Green, Chloe Tolley, Sarah Bentley, Rob Arbuckle, Marie Burstedt, James Whelan, Karen Holopigian, Kali Stasi, Brigitte Sloesen, Claudio Spera, Jean-Yves Deslandes, Anmol Mullins
INTRODUCTION: RLBP1 RP is an autosomal recessive form of retinitis pigmentosa (RP), characterized by night blindness, prolonged dark adaptation, constricted visual fields and impaired macular function. This study aimed to better understand the patient experience of RLBP1 RP and evaluate the content validity of existing patient reported outcome (PRO) instruments in this condition. METHODS: Semi-structured concept elicitation and cognitive debriefing interviews were conducted with RLBP1 RP patients in Canada and Sweden...
May 5, 2020: Advances in Therapy
Xueping Wang, Minjie Mao, Shihao Zhu, Shan Xing, Yiling Song, Lin Zhang, Peidong Chi
INTRODUCTION: Gastric cancer (GC) is the fifth most common cancer worldwide, and every year approximately 950,000 individuals are diagnosed worldwide. Our study aimed to establish an effective nomogram to predict the prognosis of GC based on inflammation biomarkers. METHODS: We retrospectively analysed GC patients from the Sun Yat-sen University Cancer Center. The nomogram was developed with a primary cohort (n = 1067), and 537 patients were included in the validation cohort...
May 3, 2020: Advances in Therapy
Katie Linden, Jonathan Mailey, Aileen Kearney, Ian B A Menown
INTRODUCTION: A large number of important clinical trials in cardiology were published or presented at major international conferences during 2019. This paper aims to offer a concise overview of these significant advances and to put them into clinical context. METHODS: Trials presented at the major international cardiology meetings during 2019 were reviewed including The American College of Cardiology (ACC), Euro PCR, The European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), and the American Heart Association (AHA)...
May 2, 2020: Advances in Therapy
Mounika Parimi, Henrik Svedsater, Quratul Ann, Mugdha Gokhale, Christen M Gray, David Hinds, Mark Nixon, Naomi Boxall
INTRODUCTION: Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2 -agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use of ICS/LABAs by comparing treatment persistence and adherence among patients with asthma in the United Kingdom initiating fluticasone furoate/vilanterol (FF/VI) versus budesonide/formoterol (BUD/FM) or beclometasone dipropionate/formoterol (BDP/FM). METHODS: A retrospective new-user active comparator database study was conducted in the IQVIA Medical Research Database...
May 2, 2020: Advances in Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"